Benlysta: still 'on trial' as HGS looks to melt physician resistance
This article was originally published in Scrip
Human Genome Sciences continues to struggle with convincing doctors to prescribe its new drug Benlysta (belimumab) for systemic lupus erythematosus, which first became available last March after US FDA approval. The product is in the early stages of being rolled out in several European countries by HGS and partner GlaxoSmithKline. With three full quarters under its belt in the US, HGS has pointed to steady quarter-to-quarter sales growth, but also concedes that physician adoption can take time.
You may also be interested in...
ChemoCentryx has successfully completed its initial public offering on Nasdaq, raising $45 million to help support its multiple R&D programmes. It sold 4.5 million shares at $10, a somewhat less ambitious debut than it had originally planned in January when it wanted to sell four million shares at $14-$16. The reduced offer is a sign of the challenging nature of the IPO market, but ChemoCentryx's assessment of its own worth was at least closer to the market’s assessment that Cempra which got its IPO away on 6 February at valuation that was less than two-thirds of that implied by its initial prospectus (scripintelligence.com, 7 February 2012).
Ampio Pharmaceuticals, a development-stage company, initially raised $15 million which was boosted to $16.9 million by the exercise of overallotments by brokers. The shares were offered at $3.25, an 8.5% discount to the closing price of $3.66 on 12 July. The market pushed them down slightly further to 3.21 on 13 July.
Verastem, a cancer stem cells startup, has moved quickly to build its pipeline just five months after an initial public offering. Management at the Cambridge, Massachusetts firm believes that recent moves have accelerated Verastem's clinical development plans by a year.